Halozyme Therapeutics, Inc.
HALO
$107.39
-$0.92-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 481.00M | 376.71M | 451.77M | 354.26M | 325.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 481.00M | 376.71M | 451.77M | 354.26M | 325.72M |
| Cost of Revenue | 106.84M | 104.80M | 110.67M | 72.49M | 63.90M |
| Gross Profit | 374.16M | 271.91M | 341.10M | 281.77M | 261.82M |
| SG&A Expenses | 57.00M | 57.88M | 63.33M | 46.09M | 41.61M |
| Depreciation & Amortization | 29.51M | 29.51M | 23.38M | 17.76M | 17.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.35M | 192.19M | 197.37M | 136.34M | 123.28M |
| Operating Income | 287.65M | 184.52M | 254.40M | 217.92M | 202.44M |
| Income Before Tax | 284.90M | 180.33M | -100.85M | 218.96M | 204.94M |
| Income Tax Expenses | 54.99M | 30.28M | 40.74M | 43.73M | 39.78M |
| Earnings from Continuing Operations | 229.91M | 150.05M | -141.59M | 175.23M | 165.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 229.91M | 150.05M | -141.59M | 175.23M | 165.16M |
| EBIT | 287.65M | 184.52M | 254.40M | 217.92M | 202.44M |
| EBITDA | 319.12M | 215.65M | 279.08M | 236.84M | 221.44M |
| EPS Basic | 1.96 | 1.27 | -1.20 | 1.49 | 1.36 |
| Normalized Basic EPS | 1.52 | 0.95 | 1.34 | 1.17 | 1.06 |
| EPS Diluted | 1.90 | 1.22 | -1.20 | 1.43 | 1.33 |
| Normalized Diluted EPS | 1.47 | 0.92 | 1.34 | 1.12 | 1.03 |
| Average Basic Shares Outstanding | 117.27M | 118.14M | 117.67M | 117.22M | 121.34M |
| Average Diluted Shares Outstanding | 121.22M | 122.88M | 117.67M | 122.33M | 124.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |